Abstract
We compared the influence of three different catechol-O-methyltransferase (COMT) inhibitors (CGP 28014, OR-611 and Ro 40-7592) on the metabolism of no-carrier-added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) in one Rhesus monkey. All three COMT inhibitors improved 6-FDOPA availability in plasma, increased the specific uptake in the brain and thus improved 6-FDOPA uptake measurements using positron emission tomography (PET). Best results were obtained with Ro 40-7592.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amidines / pharmacokinetics
-
Amidines / pharmacology
-
Animals
-
Benzophenones / pharmacokinetics
-
Benzophenones / pharmacology
-
Biological Availability
-
Brain / drug effects
-
Brain / enzymology
-
Brain / metabolism
-
Catechol O-Methyltransferase Inhibitors*
-
Catechols / pharmacokinetics
-
Catechols / pharmacology
-
Dihydroxyphenylalanine / analogs & derivatives*
-
Dihydroxyphenylalanine / metabolism
-
Dihydroxyphenylalanine / pharmacokinetics
-
Drug Evaluation, Preclinical / methods
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Female
-
Fluorine Radioisotopes
-
Macaca mulatta
-
Nitriles
-
Nitrophenols
-
Pyridones / pharmacokinetics
-
Pyridones / pharmacology
-
Tolcapone
-
Tomography, Emission-Computed
Substances
-
Amidines
-
Benzophenones
-
Catechol O-Methyltransferase Inhibitors
-
Catechols
-
Enzyme Inhibitors
-
Fluorine Radioisotopes
-
Nitriles
-
Nitrophenols
-
Pyridones
-
N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine
-
fluorodopa F 18
-
entacapone
-
Dihydroxyphenylalanine
-
Tolcapone